The Cryptosporidum study team at the UVM Vaccine Testing Center (VTC), which includes Beth Kirkpatrick, M.D., VTC director and UVM professor of medicine; Caroline Lyon, M.D., M.P.H., UVM associate professor of medicine; Christopher Huston, M.D., UVM associate professor of medicine; Catherine Larsson; and Mary Claire Walsh, PA-C, recently received a $3.3 million grant from the Bill & Melinda Gates Foundation to test new therapeutic agents against Cryptosporidium. Read the announcement in Vermont Business Magazine.
TC Cryptosporidum study team members (from left): Beth Kirkpatrick, M.D.; Caroline Lyon, M.D., M.P.H.; Christopher Huston, M.D.; Catherine Larsson; and Mary Claire Walsh, PA-C. (Photo: Marian Miller)
(MARCH 8, 2016) The Cryptosporidum study team at the UVM Vaccine Testing Center (VTC), which includes Beth Kirkpatrick, M.D., VTC director and UVM professor of medicine; Caroline Lyon, M.D., M.P.H., UVM associate professor of medicine; Christopher Huston, M.D., UVM associate professor of medicine; Catherine Larsson; and Mary Claire Walsh, PA-C, recently received a $3.3 million grant from the Bill & Melinda Gates Foundation to test new therapeutic agents against Cryptosporidium. Read the announcement in
Vermont Business Magazine.